144 related articles for article (PubMed ID: 25754137)
1. Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2.
Czeleń P; Szefler B
J Mol Model; 2015 Apr; 21(4):74. PubMed ID: 25754137
[TBL] [Abstract][Full Text] [Related]
2. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives.
Pande V; Ramos MJ
Bioorg Med Chem Lett; 2005 Dec; 15(23):5129-35. PubMed ID: 16213715
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
5. Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design.
Zhang N; Zhong R; Yan H; Jiang Y
Chem Biol Drug Des; 2011 Mar; 77(3):199-205. PubMed ID: 21244636
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
[TBL] [Abstract][Full Text] [Related]
7. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
8. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
[TBL] [Abstract][Full Text] [Related]
10. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
Gaisina IN; Gallier F; Ougolkov AV; Kim KH; Kurome T; Guo S; Holzle D; Luchini DN; Blond SY; Billadeau DD; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):1853-63. PubMed ID: 19338355
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3β inhibitors to activate Wnt/β-catenin pathway.
Yue H; Lu F; Shen C; Quan JM
Bioorg Chem; 2015 Aug; 61():21-7. PubMed ID: 26057861
[TBL] [Abstract][Full Text] [Related]
12. Structure-based approaches in the design of GSK-3 selective inhibitors.
Patel DS; Dessalew N; Iqbal P; Bharatam PV
Curr Protein Pept Sci; 2007 Aug; 8(4):352-64. PubMed ID: 17696868
[TBL] [Abstract][Full Text] [Related]
13. Binding free-energy calculation is a powerful tool for drug optimization: calculation and measurement of binding free energy for 7-azaindole derivatives to glycogen synthase kinase-3β.
Kitamura K; Tamura Y; Ueki T; Ogata K; Noda S; Himeno R; Chuman H
J Chem Inf Model; 2014 Jun; 54(6):1653-60. PubMed ID: 24884406
[TBL] [Abstract][Full Text] [Related]
14. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
17. Binding of BIS like and other ligands with the GSK-3β kinase: a combined docking and MM-PBSA study.
Jena NR
J Mol Model; 2012 Feb; 18(2):631-44. PubMed ID: 21559963
[TBL] [Abstract][Full Text] [Related]
18. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.
Motawi TM; Bustanji Y; El-Maraghy SA; Taha MO; Al Ghussein MA
J Biochem Mol Toxicol; 2013 Sep; 27(9):425-36. PubMed ID: 23784744
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.
Bustanji Y; Taha MO; Almasri IM; Al-Ghussein MA; Mohammad MK; Alkhatib HS
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):771-8. PubMed ID: 18720192
[TBL] [Abstract][Full Text] [Related]
20. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]